Evaluating Proactive Outreach for Prior Authorization Recertifications in Medicaid Patients

被引:0
|
作者
Vishwanath, Soumya [1 ]
Tran, Stephanie N. [1 ]
Pomfret, Thomas C. [1 ]
Boss, Kaelyn C. [1 ]
Tesell, Mark [1 ]
Price, Mylissa [1 ]
Alper, Caroline J. [1 ]
Muchnik, Lorean [1 ]
Clements, Karen M. [1 ]
Lenz, Kimberly [2 ]
机构
[1] UMass Chan Med Sch Commonwealth Med, 333 South St, Shrewsbury, MA 01545 USA
[2] MassHealth, Off Clin Affairs, Quincy, MA USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2021年 / 27卷 / 11期
关键词
D O I
10.37765/ajmc.2021.88783
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
OBJECTIVES: To assess the effectiveness of a proactive provider intervention in prompting prior authorization (PA) submissions or provider response prior to PA expiration for medically complex Medicaid patients. STUDY DESIGN: Pre-post outreach study with data from pharmacy claims and provider outreach. METHODS: The intervention and historical comparison (control) groups included expired PAs from December 2019 to February 2020 and from December 2018 to February 2019, respectively. Provider outreach, including telephonic and fax attempts, was conducted over a 2-week period prior to PA expiration. Outcomes were classified as positive or negative based on provider conversation coupled with the result (eg, PA submission) for the intervention group and based solely on pharmacy claims for the control group. The primary end point was the percentage of positive outcomes between the groups, analyzed via chi(2) test. The time from PA expiration to the new PA submission was evaluated via t test. RESULTS: A total of 342 outreach attempts were conducted for 270 PAs representing 193 unique patients. Outreach was more likely to result in positive outcomes in the intervention group vs no outreach in the control group (87% vs 25%; P < .00001). On average, PAs were submitted 3.5 days prior to expiration in the intervention group vs 13.0 days after expiration in the control group (t = -7.50; P < .00001). CONCLUSIONS: Proactive outreach resulted in a greater percentage of PA submissions and a significantly reduced time to PA submission. These findings provide important information for payers in guiding clinical programs to enhance continuity of care among at-risk populations.
引用
收藏
页码:E395 / E399
页数:5
相关论文
共 50 条
  • [1] Medicaid Prior Authorization Policies and Imprisonment Among Patients With Schizophrenia
    Goldman, Dana
    Fastenau, John
    Dirani, Riad
    Helland, Eric
    Joyce, Geoff
    Conrad, Ryan
    Lakdawalla, Darius
    AMERICAN JOURNAL OF MANAGED CARE, 2014, 20 (07): : 577 - 586
  • [2] Medicaid and the unconstitutional dimensions of prior authorization
    Ranjan, JN
    MICHIGAN LAW REVIEW, 2002, 101 (02) : 602 - 647
  • [3] Effects of a Medicaid Prior Authorization Policy for Pregabalin
    Margolis, Jay M.
    Johnston, Stephen S.
    Chu, Bong-Chul
    Onukwugha, Eberechukwu
    Hvidsten, Kyle
    Alvir, Jose
    Rossi, Joseph G.
    Mullins, C. Daniel
    AMERICAN JOURNAL OF MANAGED CARE, 2009, 15 (10): : E95 - E102
  • [4] Idaho Medicaid prior authorization of palivizumab (Synagis).
    Owens, CT
    Cady, PS
    Culbertson, VL
    Force, RW
    Murdock, N
    Pettinger, TK
    Steiner, JF
    PHARMACOTHERAPY, 2005, 25 (03): : 470 - 470
  • [5] Medicaid Prior Authorization and Opioid Medication Abuse and Overdose
    Cochran, Gerald
    Gordon, Adam J.
    Gellad, Walid F.
    Chang, Chung-Chou H.
    Lo-Ciganic, Wei-Hsuan
    Lobo, Carroline
    Cole, Evan
    Frazier, Winfred
    Zheng, Ping
    Kelley, David
    Donohue, Julie M.
    AMERICAN JOURNAL OF MANAGED CARE, 2017, 23 (05):
  • [6] EFFECT OF A PRIOR-AUTHORIZATION REQUIREMENT ON THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS BY MEDICAID PATIENTS
    SMALLEY, WE
    GRIFFIN, MR
    FOUGHT, RL
    SULLIVAN, L
    RAY, WA
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24): : 1612 - 1617
  • [7] Medicaid Prior Authorization Policies for Pediatric Use of Antipsychotic Medications
    Schmid, Ian
    Burcu, Mehmet
    Zito, Julie M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (09): : 966 - 968
  • [8] Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements
    Tiako, Max Jordan Nguemeni
    Dolan, Abby
    Abrams, Matthew
    Oyekanmi, Kehinde
    Meisel, Zachary
    Aronowitz, Shoshana V.
    JAMA NETWORK OPEN, 2023, 6 (06) : E2318487
  • [9] Medicaid prior authorization policies and controlled-release ocycodone
    Zerzan, J. T.
    Morden, N. E.
    Rue, T. C.
    Heagerty, P. J.
    Sullivan, S. D.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 : 68 - 68
  • [10] Medicaid prior authorization and control led-release oxycodone
    Morden, Nancy E.
    Zerzan, Judy T.
    Rue, Tessa C.
    Heagerty, Patrick J.
    Roughead, Elizabeth E.
    Soumerai, Stephen B.
    Ross-Degnan, Dennis
    Sullivan, Sean D.
    MEDICAL CARE, 2008, 46 (06) : 573 - 580